Abstract:IntroductionEndothelial progenitor cells (EPC) capable of initiating or augmenting vascular growth were recently identified within the small population of CD34-expressing cells that circulate in human peripheral blood and which are considered hematopoietic progenitor cells (HPC). Soon thereafter human HPC began to be used in clinical trials as putative sources of EPC for therapeutic vascular regeneration, especially in myocardial and critical limb ischemias. However, unlike HPC where hematopoietic efficacy is related quantitatively to CD34+ cell numbers implanted, there has been no consensus on how to measure EPC or how to assess cellular graft potency for vascular regeneration. We employed an animal model of spontaneous neovascularization to simultaneously determine whether human cells incorporate into new vessels and to quantify the effect of different putative angiogenic cells on vascularization in terms of number of vessels generated. We systematically compared competence for therapeutic angiogenesis in different sources of human cells with putative angiogenic potential, to begin to provide some rationale for optimising cell procurement for this therapy.MethodsHuman cells employed were mononuclear cells from normal peripheral blood and HPC-rich cell sources (umbilical cord blood, mobilized peripheral blood, bone marrow), CD34+ enriched or depleted subsets of these, and outgrowth cell populations from these. An established sponge implant angiogenesis model was adapted to determine the effects of different human cells on vascularization of implants in immunodeficient mice. Angiogenesis was quantified by vessel density and species of origin by immunohistochemistry.ResultsCD34+ cells from mobilized peripheral blood or umbilical cord blood HPC were the only cells to promote new vessel growth, but did not incorporate into vessels. Only endothelial outgrowth cells (EOC) incorporated into vessels, but these did not promote vessel growth.ConclusionsThese studies indicate that, since EPC are very rare, any benefit seen in clinical trials of HPC in therapeutic vascular regeneration is predominantly mediated by indirect proangiogenic effects rather than through direct incorporation of any rare EPC contained within these sources. It should be possible to produce autologous EOC for therapeutic use, and evaluate the effect of EPC distinct from, or in synergy with, the proangiogenic effects of HPC therapies.

Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks

Endothelial progenitor cells restore renal function in chronic experimental renovascular disease

Therapeutic angiogenesis by transplantation of human embryonic stem cell-derived CD133+ endothelial progenitor cells for cardiac repair.

Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients with Idiopathic Pulmonary Arterial Hypertension: a Pilot Randomized Controlled Trial.

Extracellular Vesicle Transplantation Is Beneficial for Acute Kidney Injury

Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration

Mri of Autotransplantation of Bone Marrow-Derived Stem-Progenitor Cells: Toward Cell-Based Repair of Injured Arteries

A Preliminary Study of the Therapeutic Role of Human Early Fetal Aorta-derived Endothelial Progenitor Cells in Inhibiting Carotid Artery Neointimal Hyperplasia.

Systematic assessment in an animal model of the angiogenic potential of different human cell sources for therapeutic revascularization

Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury

Vascular Repair by Endothelial Progenitor Cells

Vascular Regeneration by Stem/Progenitor Cells.

Recovery of Renal Function following Kidney-Specific VEGF Therapy in Experimental Renovascular Disease

Frontiers in nephrology: the evolving therapeutic applications of endothelial progenitor cells

Human cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model

NRP1-expressing monocyte/macrophages promote arteriogenesis in the ischemic limb

Novel cell therapy with ex vivo cultured peripheral blood mononuclear cells significantly impacts angiogenesis in the murine ischemic limb model

Human cord blood CD133+ cells exacerbate ischemic acute kidney injury in mice

Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132.

Nonbone Marrow CD34+Cells Are Crucial for Endothelial Repair of Injured Artery

Progenitor-like cells derived from mouse kidney protect against renal fibrosis in a remnant kidney model via decreased endothelial mesenchymal transition